Abstract
It is universally accepted that somatic alterations (i.e., point mutations, small insertions and deletions, rearrangements, gains and losses) occur at the DNA level in cancer. These somatic events can drive tumorigenesis, metastatic progression, and/or drug resistance. More importantly, specific somatic alterations are intimately tied to companion targeted therapeutics. Recent technological advances in the form of Next Generation Sequencing technologies now provide us with platforms to interrogate entire human genomes at a fraction of the time and cost compared to more traditional sequencing technologies. These technologies are already being used to survey the global somatic landscape of tumors across large cohorts. As many cancer types disproportionately affect underrepresented populations, this session will highlight new findings from deep genomic profiling of tumors from individuals from diverse populations. Ultimately it is our hope to glean new insights into the possible role of somatic events.
Citation Format: John D. Carpten. Genome sequencing of triple-negative breast cancer in African American women. [abstract]. In: Proceedings of the Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2012 Oct 27-30; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(10 Suppl):Abstract nr PL07-02.